Lek’s Site in Prevalje Welcomed a Number of Local Residents
- Open Door Day, organised by Lek Prevalje, has attracted residents as well as visitors from other Carinthian towns.
- They got to know about Lek’s activities, plans for future development, pharmaceutical production and advanced system of environmental management.
- Lek will continue to expand employment in Prevalje and invest in the knowledge of its employees and innovative technologies.
Today, Lek organised an Open Door Day at its Prevalje site. More than 150 visitors had an opportunity to have a closer look at the production and organisation of work, among others, under the expert guidance of Lek’s associates.
Zlatko Ajd, Head Anti-infectives Prevalje, and Katarina Klemenc, Head Corporate Communications, presented the visitors with details of the site’s development, which has been particularly intense recently, as well as the latest investment in building a new factory. It will stand in the close vicinity of the existing facilities and will significantly pronounce Lek’s Prevalje site in the coming years. The foundation stone laying ceremony will be held on Tuesday, April 11, 2017. The visitors also had an opportunity to get acquainted with the new employment opportunities and career paths presented by Maja Sušec, head of the Prevalje analytical laboratory for quality control.
Lek’s site in Prevalje manufactures a finished pharmaceutical product, a broad-spectrum antibiotic that belongs to the most important of Sandoz products and is sold in more than 60 most demanding markets around the world. Due to high demand for this product, the production volume has been continuously growing, reaching an average of more than ten-percent annual growth.
Lek’s site in Prevalje has developed to become one of the key economic entities in Carinthia and positioned itself as a stable employer, one of the most important in the region. Over the last four years, the number of employees has increased by 40%. More than 95% of the employees come from the municipalities of the Mežica and Drava valley; more than half of them are women. Currently, there are more than 240 employees and employment will continue to expand.
For more than four decades, Lek Prevalje has been actively involved in the life of the local community. In recent years, Lek has helped a number of associations and institutions, including the Voluntary Fire Brigades Prevalje; Mountain Rescue Service –Prevalje Unit; Regional Red Cross Committee; Prevalje Home for the Elderly; Prevalje Volleyball Club; Primary School Franjo Golob Prevalje; Primary School Podgorje; Swimming Club Fužinar; Carinthian Cultural Association and Pensioners’ Association Prevalje. Together with the Slovenian Mountain Rescue Association, Lek organised workshops Children Learn to Help at the primary School Franjo Golob Prevalje; invited “Helping Paws” to the Prevalje Kindergarten; organised a hike with Petra Majdič as part of Autumn Days, and enabled, with the support of the Red Noses, the Caravan Orchestra show at the Center for Training, Occupation and Care (CUDV) in the Carinthian town of Črna.
Through volunteering and blood donation, Lek Prevalje has been offering a helping hand in the local environment, in the Home for the Elderly in Fara; Altra Center and elsewhere, for over a decade. For the local community, Open Door Days have also been organised for many years.
Lek Prevalje implements the principle of responsible business conduct. It strictly follows the requirements of health, safety and environmental legislation and uniform Novartis standards that are sometimes more stringent than national laws. The visitors learned about a comprehensive and advanced system of environment management at the site, which has already been aligned with the ISO 14001:2015 standard. Lek is the first and only pharmaceutical company in Slovenia to be included in the European Union Eco-management and Audit Scheme (EMAS) for responsible management of environmental impacts, while the Anti-infective Unit Prevalje is the only one among the economic entities in Carinthia to be included.
Lek, a Sandoz company, is one of the key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a key global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar active ingredients and products; a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and the Commonwealth of Independent States (CIS), and is responsible for marketing and sales of Sandoz products on the Slovenian market. For further information, please visit www.lek.si.
Sandoz is a global leader in generic and biosimilar pharmaceuticals. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2016 sales of USD 10.1 billion. In 2016, our products reached more than 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global (link is external).
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com/.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32